Takeda Pharmaceutical Co(JP:4502)
¥6,825.00+152.00 (+2.28%)
JP:4502
Takeda Pharmaceutical Co earnings date
¥6,825.00
At close:+152.00 (+2.28%)
Want to see JP:4502 full AI Analyst Report?
Takeda Pharmaceutical Co (4502) Q2 2019 Earnings Report
10 Followers
JP:4502 Q2 2019 EPS Results
- Actual EPS
- JPY 51.48
- Consensus EPS
- ―
- Beat/Miss
- ―
- One Year Ago EPS
- JPY 88.58
JP:4502 Q2 2019 Revenue Results
- Actual Revenue
- JPY 1.21T
- Expected Revenue
- ―
- Beat/Miss
- ―
- YoY Revenue Growth
- +95.53%
Earnings Announcement Details
- Quarter
- Q2 2019
- Date
- 10/31/2019
- Time
- Before Open
- Conference Call
- Thursday, October 31, 2019
JP:4502 Upcoming Earnings
Takeda Pharmaceutical Co's next earnings date is estimated for January 28, 2027, based on past reporting schedules.
Q2 2019 Earnings Call Audio
No earnings call audio is available for this earnings event.
Q2 2019 Earnings Slide Deck
No slide deck is available for this earnings event.
Q2 2019 Earnings Call Summary
No earnings call summary is available for this earnings event.
JP:4502 Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Jan 28, 2027 | 2026 (Q3) | 44.55- | 65.74 | ― | ― |
| Oct 29, 2026 | 2026 (Q2) | 45.38120.88 | -7.83 | 1643.81% (+128.71) | |
| Jul 30, 2026 | 2026 (Q1) | 54.3871.65 | 79.4 | -9.76% (-7.75) | |
| May 13, 2026 | 2025 (Q4) | -24.02-15.56 | -66 | 76.42% (+50.44) | |
| Jan 28, 2026 | 2025 (Q3) | 43.1465.74 | 15.15 | 333.93% (+50.59) | |
| Oct 30, 2025 | 2025 (Q2) | 20.73-7.83 | 58.21 | -113.45% (-66.04) | |
| Jul 30, 2025 | 2025 (Q1) | 49.5679.40 | 61 | 30.16% (+18.40) | |
| May 08, 2025 | 2024 (Q4) | -8.84-66.00 | -2.1 | -3042.86% (-63.90) | |
| Jan 30, 2025 | 2024 (Q3) | 26.2015.15 | 67.59 | -77.59% (-52.44) | |
| Oct 31, 2024 | 2024 (Q2) | 37.0558.21 | -31 | 287.77% (+89.21) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat Missed
